Neuronal nicotinic receptor inhibition for treating mood disorders preliminary controlled evidence with mecamylamine
- 30 October 2002
- journal article
- clinical trial
- Published by Hindawi Limited in Depression and Anxiety
- Vol. 16 (3) , 89-92
- https://doi.org/10.1002/da.10035
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Mecamylamine Modifies the Pharmacokinetics and Reinforcing Effects of AlcoholAlcohol, Clinical and Experimental Research, 2002
- Multicenter, Double-Blind, Placebo-Controlled Study of Mecamylamine Monotherapy for Tourette's DisorderJournal of the American Academy of Child & Adolescent Psychiatry, 2001
- Mecamylamine: new therapeutic uses and toxicity/risk profileClinical Therapeutics, 2001
- Mecamylamine in Tourette's Syndrome: A Two-Year Retrospective Case StudyJournal of Child and Adolescent Psychopharmacology, 2000
- A Nicotine Antagonist, Mecamylamine, Reduces Cue-Induced Cocaine Craving in Cocaine-Dependent SubjectsNeuropsychopharmacology, 1999
- Antidepressant effects of nicotine in an animal model of depressionPsychopharmacology, 1999
- Treatment of Tourette's syndrome with mecamylamineThe Lancet, 1998
- Cigarette Smoking and Major DepressionJournal of Addictive Diseases, 1998
- Nicotine–mecamylamine treatment for smoking cessation: The role of pre-cessation therapy.Experimental and Clinical Psychopharmacology, 1998
- Regulation by nicotine of its own receptorsDrug Development Research, 1996